Chemokine receptor antagonist peptide, viral MIP-II, protects the brain against focal cerebral ischemia in mice

75Citations
Citations of this article
29Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

The authors previously reported that mRNA for macrophage inflammatory protein-1α (MIP-1 α), a member of the CC chemokines, was expressed in glial cells after focal cerebral ischemia in rats. However, the function of chemokines in the ischemic brain remains unclear. Recently, viral macrophage inflammatory protein-II (vMIP-II), a chemokine analogue encoded by human herpesvirus-8 DNA, has been demonstrated to have antagonistic activity at several chemokine receptors. In the present study, the effects of vMIP-II and MIP-1 α on ischemic brain injury were examined in mice to elucidate the roles of chemokines endogenously produced in the ischemic brain. Intracerebroventricular injection of vMIP-II (0.01-1 μg) reduced infarct volume in a dose-dependent manner when examined 48 hours after 1-hour middle cerebral artry occlusion followed by reperfusion. However, 1 μg MIP-1α increased infarct volume in the cortical region. These results supported the possibility that chemokines endogenously produced in the brain are involved in ischemic injury, and that chemokine receptors are potential targets for therapeutic intervention of stroke.

Cite

CITATION STYLE

APA

Takami, S., Minami, M., Nagata, I., Namura, S., & Satoh, M. (2001). Chemokine receptor antagonist peptide, viral MIP-II, protects the brain against focal cerebral ischemia in mice. Journal of Cerebral Blood Flow and Metabolism, 21(12), 1430–1435. https://doi.org/10.1097/00004647-200112000-00007

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free